Get Updates


FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

| More


Check out this new video w/FORCE & 15 other cancer orgs representing patients, physicians, nurses, & social workers. Oppose Graham-Cassidy! See Video...

FORCE reps were in St. Louis today for an ICER hearing on the value and cost of PARP inhibitors for ovarian cancer patients.

Advocates took part in the Rally for Medical Research Capitol Hill Day Training, preparing them to advocate for increased NIH research funding.

FORCE participated in the Blueprint for Breakthroughs: Charting the Course for Precision Medicine workshop, providing the perspective of the patient community.

Today, FORCE submitted comments to ICER expressing concerns about its draft report “Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value.”

A FORCE rep spoke today about effectively working with patient groups at the 13th annual Medical Device Coverage & Reimbursement conference.

We joined 133 orgs in supporting the I Am Essential coalition letter in response to the HHS RFI on how to "create a more flexible, streamlined approach to the regulatory structure of the individual and small group markets."

Lisa Schlager, FORCE VP of Community Affairs & Public Policy, attended the NCCN Policy Summit on Ensuring Patient Safety and Access in Cancer Care.
Summit Overview

FORCE joined 60 other orgs in a letter to the FDA with comments on the proposed Office of Patient Affairs.
Read comments...

FORCE joined The Ad Hoc Group for Medical Research, representing over 300 organizations, in recommending a $2 billion FY18 increase for NIH, in addition to funds included in the 21st Century Cures Act for targeted initiatives.



Take Action

Read our statement in response to the FDA decision, and our testimony presented at the FDA hearing on Avastin.

If you are a woman living with advanced hereditary breast cancer please take our metastatic breast cancer survey and help us advocate for more options for treating hereditary breast cancer.

The cancer drug Avastin has been studied as a treatment for advanced breast and ovarian cancer. Not all women with advanced cancer respond equally to the medication. The FDA has decided that the benefits of Avastin do not outweigh the risks for women with advanced breast cancer and the agency has removed Avastin from the list of approved breast cancer therapies. While FORCE respects the FDA's decision, we are disappointed with this outcome. There are women with advanced breast cancer for whom Avastin appears to work well. FORCE has prepared a statement in response to the FDA recent ruling.

FORCE's concerns

  • FORCE is concerned that this label change will restrict access to the medication for women who are currently on and benefiting from the drug.
  • We are concerned that this change will restrict access for women who are newly diagnosed with metastatic breast and ovarian cancer who might benefit from the medication but will not be presented with it as a treatment option.
  • Further, we are concerned that insurance companies may use the FDA decision to restrict reimbursement even for those women who are currently on and responding to the medication.

More research needed

More research is needed to better determine which portion of breast cancer patients most benefit from Avastin. The decision of whether or not a woman with stage IV breast cancer should have access to Avastin should be made after discussion and consideration of benefits vs. risks with her health care team.

FORCE:Facing Our Risk of Cancer Empowered